Acceleron Pharma Inc.
Nov 30, 2016

Acceleron Pharma to Host Conference Call and Webcast to Review Data Presented at the 58th American Society of Hematology Annual Meeting and Exposition

- Management to review highlights from luspatercept and sotatercept clinical presentations -

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN) a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics to treat serious and rare diseases, today announced that the Company will host a live conference call and webcast on Monday, December 5, 2016 at 9:00 a.m. EST (6:00 a.m. PST) to discuss luspatercept and sotatercept Phase 2 clinical data being presented at the 58th American Society of Hematology Annual Meeting and Exposition (ASH) taking place December 3-6, 2016 in San Diego, CA.

Participants can access the live conference call by dialing 877-312-5848 (domestic) or 253-237-1155 (international) and referring to the Acceleron ASH update.

The live webcast can be accessed on the Investors page of the Company's website at www.acceleronpharma.com.

A replay of the webcast will be available approximately two hours after the event on the Acceleron website.

About Acceleron

Acceleron is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics to treat serious and rare diseases. Its pioneering research platform leverages the powerful biology behind the body's ability to rebuild and repair its own cells and tissues. This approach to drug discovery has generated four therapeutic candidates that are currently in clinical trials. The Company's lead therapeutic candidate, luspatercept, is being evaluated in Phase 3 studies for the treatment of the hematologic diseases, myelodysplastic syndromes (MDS) and beta-thalassemia under a global partnership with Celgene Corp. Acceleron is also advancing clinical programs in the fields of oncology and neuromuscular diseases and has a comprehensive preclinical research effort targeting fibrotic and other serious diseases.

For more information, please visit www.acceleronpharma.com. Follow Acceleron on Social Media: @AcceleronPharma and LinkedIn.

Acceleron Pharma Inc.
Todd James, IRC, 617-649-9393
Senior Director, Investor Relations and Corporate Communications
or
Media:
BMC Communications
Brad Miles, 646-513-3125

Source: Acceleron Pharma

News Provided by Acquire Media